merscov
zoonot
viru
dromedari
camel
camelu
dromedariu
reservoir
host
sourc
zoonot
transmiss
dromedari
appear
mildli
symptomat
follow
infect
present
signific
reservoir
risk
spillov
merscov
rna
detect
dromedari
camel
number
countri
includ
egypt
oman
qatar
saudi
arabia
evid
suggest
merscov
also
widespread
middl
east
africa
south
infect
camel
notifi
individu
close
frequent
contact
dromedari
higher
risk
merscov
infect
gener
coronavirus
famili
virus
caus
diseas
human
rang
common
cold
sever
acut
respiratori
syndrom
sar
clinic
spectrum
mer
rang
symptom
asymptomat
infect
mild
symptom
includ
fever
cough
gastrointestin
ill
short
breath
sever
diseas
includ
pneumonia
acut
respiratori
distress
syndrom
sever
case
mer
result
respiratori
failur
requir
mechan
ventil
support
intens
care
risk
factor
sever
diseas
includ
weaken
immun
system
older
age
year
comorbid
diabet
cancer
renal
diseas
chronic
lung
humantohuman
transmiss
spread
close
unprotect
human
contact
half
report
mer
case
occur
nosocomi
prevent
nosocomi
infect
other
recommend
use
standard
infect
prevent
control
measur
care
also
recommend
contact
trace
symptomat
asymptomat
close
contact
primari
patient
conduct
molecular
epidemiolog
merscov
chang
significantli
sinc
initi
human
case
detect
current
viru
remain
ident
sequenc
seen
first
human
case
well
archiv
camel
sera
increas
pathogen
observ
anim
genet
mutat
could
impact
detect
immunotherapi
vaccin
develop
sequenc
merscov
strain
camel
human
zoonot
spillov
import
regularli
conduct
affect
member
state
person
commun
current
prophylact
therapeut
intervent
proven
efficaci
coronaviru
infect
without
specif
therapi
mer
treatment
effect
mer
therapeut
still
earli
stage
research
evalu
sever
broadspectrum
antivir
agent
includ
viral
methyltransferas
nucleotid
shown
vitro
activ
merscov
earli
result
novel
mersspecif
therapeut
inhibit
viral
replic
specif
neutralis
activ
r
blueprint
mer
call
three
type
vaccin
dromedari
camel
vaccin
prevent
zoonot
transmiss
human
vaccin
longterm
protect
person
high
exposur
risk
human
vaccin
reactiv
use
outbreak
merscov
vaccin
earli
stage
one
candid
vaccin
phase
clinic
trial
neutralis
monoclon
antibodi
design
target
merscov
spike
modifi
vaccinia
ankara
vector
also
strong
vaccin
none
yet
advanc
clinic
trial
acceler
process
coalit
epidem
prepared
innov
recent
launch
call
propos
develop
human
merscov
vaccin
order
engag
develop
interest
support
laboratori
guidelin
recommend
nucleic
acid
amplif
test
naat
diagnosi
use
serolog
diagnosi
naat
suspect
patient
singl
neg
test
result
exclud
diagnosi
repeat
sequenti
sampl
test
strongli
recommend
kinet
merscov
infect
shown
vari
wide
across
prompt
detail
investig
viral
antibodi
dynam
across
broad
rang
sampl
type
diseas
state
host
best
naat
test
sensit
achiev
use
specimen
lower
respiratori
tract
sputum
tracheal
aspir
bronchoalveolar
lavag
merscov
replic
occur
higher
prolong
level
merscov
rna
typic
merscov
viral
load
gener
higher
sever
case
prolong
viral
shed
mild
case
viral
load
concentr
may
undetect
earlystag
infect
gener
peak
second
week
symptom
onset
drop
undetect
survivor
fourth
week
onset
upper
respiratori
tract
specimen
nasopharyng
oropharyng
swab
may
also
use
demonstr
lower
viral
load
test
neg
mild
possibl
upper
lower
respiratori
tract
sampl
advis
specimen
outsid
respiratori
tract
recommend
diagnosi
test
neg
sever
mild
present
viral
rna
detect
stool
sampl
copiesml
serum
sampl
copiesml
urin
copiesml
like
indic
sever
typic
preced
poor
clinic
serolog
diagnosi
made
use
pair
sampl
often
use
research
rather
diagnost
purpos
prefer
initi
sampl
collect
first
week
ill
second
collect
week
later
singl
serum
sampl
collect
occur
least
week
onset
symptom
determin
probabl
case
tabl
present
overview
implement
requir
merscov
diagnost
detail
commerci
product
inform
present
onlin
supplementari
tabl
molecular
diagnost
naat
eg
pcr
typic
requir
sophist
laboratori
infrastructur
includ
biosafeti
serolog
test
elisa
indirect
immunofluoresc
test
iift
run
benchtop
modest
laboratori
environ
depend
sampl
prepar
pointofcar
poc
test
design
use
outsid
tradit
laboratori
nearpoc
test
defin
rapid
use
laboratori
near
patient
autom
easi
use
tradit
laboratori
poc
test
lowcomplex
rapid
diagnost
test
rdt
use
bedsid
typic
noninvas
sampl
minim
train
inhous
test
describ
section
commerci
sourc
list
onlin
supplementari
tabl
naat
current
standard
merscov
diagnosi
test
typic
revers
transcriptas
pcr
rtpcr
highest
sensit
earliest
time
point
acut
phase
infect
follow
guidelin
two
differ
target
merscov
need
detect
rtpcr
confirm
case
merscov
assay
detect
upstream
envelop
gene
upe
follow
confirm
open
read
frame
gene
nucleocapsid
n
gene
confirm
commerci
pcr
test
perform
parallel
screen
upe
gene
confirm
n
gene
commonli
upe
initi
naat
test
merscov
develop
inhous
test
follow
first
detect
merscov
middl
inhous
test
necessarili
subject
qualiti
control
regul
may
rigor
valid
case
inhous
test
eventu
develop
commerci
product
collabor
licens
commerci
assay
may
undergo
intern
andor
incountri
regulatori
process
market
independ
evalu
sensit
specif
limit
sever
commerci
naat
test
avail
merscov
includ
duplex
multiplex
panel
see
onlin
supplementari
tabl
serolog
wide
perform
diagnos
acut
merscov
infect
howev
use
tool
determin
extent
infect
around
cluster
seroepidemiolog
studi
anim
human
seroconvers
typic
occur
second
third
week
symptom
onset
data
suggest
low
antibodi
titr
second
week
delay
seroconvers
close
associ
mortal
high
viral
merscov
seroconvers
may
observ
patient
notabl
mild
asymptomat
infect
show
crossreact
antibodi
serolog
method
detect
antibodi
merscov
includ
elisa
iift
neutralis
test
merscov
serolog
assay
employ
commerci
reagent
proprietari
monoclon
antibodi
captur
mani
merscov
elisa
test
label
research
use
littl
clinic
valid
data
avail
similar
elisa
iift
use
difficult
evalu
specif
antigen
individu
enzym
immunoassay
prefer
broader
analysi
immobilis
specimen
iift
microscopi
assay
probe
entir
antigen
spectrum
specimen
often
design
simultan
detect
antibodi
biochem
distinct
antigen
neutralis
method
detect
antimerscov
antibodi
activ
via
inhibit
infect
perform
plaqu
reduct
neutralis
microneutralis
mn
pseudoparticl
neutralis
ppnt
mn
labourintens
slow
requir
least
day
result
neutralis
techniqu
ppnt
requir
biosafeti
level
contain
involv
live
viru
rdt
leverag
antibodyantigen
captur
agent
elisa
later
flow
strip
enabl
fast
min
time
result
lower
detect
sensit
followup
confirmatori
test
therefor
requir
rdt
typic
pair
minim
invas
specimen
collect
blood
oral
fluid
nasal
swab
use
minim
train
outsid
laboratori
set
earli
prototyp
merscov
rdt
commerci
rdt
detect
merscov
camel
human
avail
onlin
supplementari
tabl
human
merscov
rdt
appear
wide
use
perhap
due
invas
process
requir
lower
respiratori
specimen
well
sensit
issu
upper
respiratori
specimen
camel
merscov
rdt
use
upper
respiratori
specimen
howev
test
sensit
vari
depend
specimen
sampl
infect
earli
stage
symptom
merscov
infect
mimic
diseas
influenza
pneumonia
sar
respiratori
infect
syndrom
approach
involv
test
pathogen
base
syndrom
fever
acut
respiratori
distress
shift
individu
test
multiplex
panel
quickli
identifi
elimin
like
pathogen
singl
specimen
analysi
circul
reservoir
multiplex
microbeadbas
immunoassay
use
detect
igg
antibodi
multipl
multiplex
syndrom
panel
includ
merscov
demonstr
use
pcrbase
panel
includ
merscov
show
similar
limit
detect
singl
commerci
respiratori
panel
test
includ
merscov
also
recent
develop
see
onlin
supplementari
tabl
need
intern
consensu
adopt
minimum
standard
test
use
diagnosi
surveil
research
follow
recommend
algorithm
human
oie
recommend
anim
harmonis
test
process
achiev
build
consensu
capac
across
intern
incountri
laboratori
order
enabl
sustain
capac
rapid
outbreak
respons
laboratori
must
access
highqual
reagent
instrument
along
technic
support
coldchain
transport
necessari
addit
intern
refer
panel
would
achiev
standardis
train
extern
qualiti
assess
eqa
qualiti
control
build
mandatori
case
intern
merscov
data
share
platform
includ
case
exposur
histori
sequenc
data
would
greatli
facilit
knowledg
base
across
merscov
understand
merscov
viral
dynam
across
broad
rang
specimen
type
critic
establish
limit
detect
time
diagnost
order
make
greatest
impact
diagnosi
case
manag
surveil
ensur
test
appropri
sensit
specif
major
challeng
develop
diagnost
novel
rare
pathogen
often
limit
suppli
wellcharacteris
clinic
materi
especi
earli
stage
outbreak
clinic
evalu
must
often
perform
affect
countri
laboratori
work
close
ministri
health
typic
small
number
patient
specimen
share
outsid
affect
countri
due
strict
import
export
regul
particularli
dualus
specif
provis
nagoya
protocol
signific
impact
access
genet
materi
commerci
noncommerci
particular
develop
valid
process
new
diagnost
could
acceler
wellcharacteris
specimen
refer
standard
could
easili
obtain
eqa
use
evalu
test
perform
shown
evalu
inhous
commerci
assay
recent
global
profici
test
programm
use
assess
laboratori
detect
even
valid
substanti
amount
refer
materi
requir
qualiti
control
often
manufactur
must
develop
calibr
standard
maintain
suppli
control
lottolot
variabl
intern
refer
standard
qualifi
specimen
panel
acceler
develop
valid
diagnost
test
particular
intern
biolog
refer
prepar
provid
member
state
serv
refer
sourc
ensur
reliabl
vitro
biolog
diagnost
procedur
use
diagnosi
diseas
treatment
monitor
includ
merscov
sever
intern
institut
also
provid
specimen
valid
group
typic
defin
pathogendiseas
focu
correspond
archiv
biolog
refer
materi
howev
suppli
may
limit
see
onlin
supplementari
materi
current
merscov
diagnosi
pcr
requir
laboratori
sophist
facil
biosafeti
cabinet
turnaround
time
receiv
test
result
take
day
week
depend
laboratori
proxim
sampl
transport
option
laboratori
process
infrastructur
requir
place
pcr
system
refer
laboratori
may
ideal
diseas
like
merscov
recommend
immedi
isol
infect
detect
across
varieti
nimbl
approach
need
merscov
case
detect
border
cross
anim
surveil
quarantin
target
faooiewho
mer
technic
work
group
given
clear
call
develop
rdt
improv
identif
isol
primari
human
case
healthcar
serolog
rdt
ideal
low
infrastructur
set
primari
health
clinic
home
field
test
howev
specimen
collect
remain
key
challeng
merscov
recommend
lower
respiratori
specimen
difficult
obtain
outsid
hospit
set
upper
respiratori
specimen
nasal
swab
easi
obtain
work
well
conjunct
rdt
camel
specimen
gener
low
viru
titr
human
thu
limit
current
use
rdt
anim
improv
current
rdt
detect
chemistri
feasibl
may
support
futur
use
test
human
least
rapid
triag
highli
infecti
case
poc
nearpoc
microfluid
platform
enabl
flexibl
still
highli
sensit
approach
nearpati
naat
test
decentralis
set
nearpoc
naat
platform
compact
selfcontain
autom
sampl
prepar
process
minim
laboratori
set
healthcar
worker
train
oper
within
recent
public
describ
merscov
assay
design
poc
loopmedi
isotherm
amplif
paperbas
sensor
howev
merscov
assay
current
avail
exist
nearpoc
platform
given
pcr
standard
merscov
diagnosi
would
highli
desir
autom
selfcontain
naat
assay
readili
deploy
field
clinic
set
syndrom
test
valuabl
earli
stage
outbreak
order
distinguish
merscov
respiratori
infect
identifi
case
syndrom
panel
could
effect
expedit
pathogen
outbreak
identif
especi
technolog
screen
multipl
pathogen
use
panel
approach
definit
diagnosi
could
enabl
time
decis
triag
treatment
infect
control
contact
pertest
cost
rise
test
complex
includ
addit
reagent
sophist
instrument
rapid
effici
diagnosi
scheme
impact
intervent
infect
control
costsav
respiratori
diseas
region
regionspecif
panel
may
multiplex
panel
offer
altern
bundl
test
paradigm
howev
routin
use
market
small
develop
may
reluct
support
test
diagnost
use
requir
addit
invest
valid
regul
surveil
effect
method
identifi
initi
stage
outbreak
requir
routin
effect
sampl
impact
surveil
test
depend
test
sensit
specif
sampl
rate
kinet
diseas
whether
target
anim
human
popul
surveil
sampl
perform
field
either
populationbas
hot
spot
sampl
merscov
may
difficult
expens
implement
routin
surveil
dromedari
camel
stock
repres
significantli
larg
reservoir
may
suffer
mild
effect
merscov
infect
ideal
surveil
tool
would
highli
sensit
fieldappropri
screen
test
pertest
cost
also
import
factor
along
eas
implement
review
identifi
diagnost
current
avail
merscov
highlight
ongo
challeng
caus
critic
gap
diagnost
support
outbreak
manag
rdt
offer
potenti
rapid
poc
screen
merscov
howev
practic
limit
implement
lower
respiratori
sampl
acquisit
outsid
hospit
set
limit
feasibl
poc
nearpoc
naat
platform
provid
opportun
implement
autom
selfcontain
test
hospit
clinic
limit
train
endemicpron
area
expans
test
menu
option
exist
poc
nearpoc
naat
platform
strengthen
incountri
respons
capac
endem
diseas
simultan
ensur
countri
prepar
futur
pandem
syndrom
multiplex
panel
may
expedit
differenti
diagnosi
merscov
endem
respiratori
diseas
analysi
need
inform
implement
costeffect
context
region
season
detect
also
need
sensit
serolog
assay
lower
cost
minimum
crossreact
use
surveil
tool
detail
understand
merscov
viral
antibodi
kinet
need
across
broad
rang
sampl
type
order
optimis
use
exist
assay
address
ongo
technic
challeng
detect
mild
asymptomat
infect
surveil
continu
import
detect
merscov
spillov
event
howev
question
remain
costeffect
routin
screen
larg
reservoir
camel
popul
addit
support
toward
sampl
biobank
wellcharacteris
specimen
refer
standard
facilit
diagnost
develop
qualiti
assur
merscov
diagnost
worldwid
order
achiev
goal
r
blueprint
effort
identifi
key
target
product
profil
diagnost
order
mobilis
fund
resourc
support
develop
implement
critic
need
test
